VIPR2
Basic information
Region (hg38): 7:159028175-159144867
Links
Transcripts
Transcript IDs starting with ENST are treated as Ensembl, all others as RefSeq. Showing 4 of 12.
| Transcript ID | Protein ID | Coding exons | MANE Select | MANE Plus Clinical |
|---|---|---|---|---|
ENST00000262178.7 | ENSP00000262178.2 | 13 | yes | - |
ENST00000377633.7 | ENSP00000366860.3 | 10 | - | - |
ENST00000402066.5 | ENSP00000384497.1 | 13 | - | - |
ENST00000421760.2 | ENSP00000402690.2 | 3 | - | - |
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (54 variants)
- not_provided (8 variants)
- Myoepithelial_tumor (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VIPR2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000003382.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 2 | 5 | |||
| missense | 52 | 3 | 1 | 56 | ||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 0 | 0 | 53 | 6 | 3 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| VIPR2 | protein_coding | protein_coding | ENST00000262178 | 13 | 116784 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 125682 | 0 | 66 | 125748 | 0.000262 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.283 | 230 | 242 | 0.949 | 0.0000136 | 2821 |
| Missense in Polyphen | 88 | 103.33 | 0.85167 | 1214 | ||
| Synonymous | -0.283 | 112 | 108 | 1.03 | 0.00000702 | 860 |
| Loss of Function | 1.35 | 20 | 27.7 | 0.723 | 0.00000156 | 284 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000717 | 0.000716 |
| Ashkenazi Jewish | 0.0000993 | 0.0000992 |
| East Asian | 0.000169 | 0.000163 |
| Finnish | 0.0000522 | 0.0000462 |
| European (Non-Finnish) | 0.000264 | 0.000264 |
| Middle Eastern | 0.000169 | 0.000163 |
| South Asian | 0.000392 | 0.000392 |
| Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C. {ECO:0000269|PubMed:8926282}.;
- Pathway
- cAMP signaling pathway - Homo sapiens (human);Neuroactive ligand-receptor interaction - Homo sapiens (human);GPCRs, Class B Secretin-like;Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways;Signaling by GPCR;Signal Transduction;G alpha (s) signalling events;Glucagon-type ligand receptors;Class B/2 (Secretin family receptors);GPCR ligand binding;GPCR downstream signalling
(Consensus)
Recessive Scores
- pRec
- 0.167
Intolerance Scores
- loftool
- 0.867
- rvis_EVS
- -0.62
- rvis_percentile_EVS
- 17.31
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.256
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- signal transduction;cell surface receptor signaling pathway;G protein-coupled receptor signaling pathway;activation of adenylate cyclase activity;cell-cell signaling;negative regulation of smooth muscle cell proliferation
- Cellular component
- plasma membrane;integral component of plasma membrane
- Molecular function
- G protein-coupled receptor activity;vasoactive intestinal polypeptide receptor activity;G protein-coupled peptide receptor activity;peptide hormone binding